Answers are grounded in this paper and cite their sources.
Reliable cell-based assays and animal models have been developed for evaluating agents against hepatitis B virus. Although much progress has been made, in vitro and in vivo assays for hepatitis C virus are still on the horizon. Advances towards establishing inexpensive and reliable experimental models have accelerated the development of therapeutic modalities for these life-threatening viral infections. The characterization of well-defined viral targets coupled with improved molecular diagnostic technologies have illuminated this field.
No takes yet. Share an insight, caveat, or question.
Schinazi et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: